Related Experiment Video

Updated: Jan 21, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

18.8K

Small molecule HDAC inhibitors: Promising agents for breast cancer treatment

Meiling Huang1, Jian Zhang2, Changjiao Yan1

  • 1Department of Thyroid, Breast and Vascular Surgery, Xijing Hospital, The Fourth Military Medical University, Xi'an 710032, PR China.

Bioorganic Chemistry
|August 14, 2019
PubMed

Insights

Histone deacetylase inhibitors (HDACIs) show promise for breast cancer treatment, particularly in combination therapies. Further research and clinical trials are essential for developing novel HDACIs and advancing treatments.

Area of Science:

  • Oncology
  • Epigenetics
  • Pharmacology

Background:

  • Breast cancer is a leading cause of death globally, characterized by complex heterogeneity.
  • Epigenetic alterations, including those involving histone deacetylases (HDACs), are critical in cancer development.
  • HDAC inhibitors (HDACIs) are emerging as potential therapeutic agents for cancer treatment.

Purpose of the Study:

  • To review the mechanisms and classifications of HDACs and HDACIs.
  • To explore the association between HDACs and breast cancer.
  • To summarize the structure-activity relationships, pharmacokinetics, toxicology, and clinical studies of HDACIs in breast cancer.

Main Methods:

  • Literature review of HDACs, HDACIs, and their role in breast cancer.
  • Analysis of structure-activity relationships (SAR) of HDACIs.
  • Compilation of data from registered clinical studies for breast cancer treatment.

Main Results:

  • HDACIs demonstrate efficacy in breast cancer treatment, especially when combined with other agents.
  • Significant research exists on HDACIs, including their classification, SAR, and properties.
  • Clinical studies indicate the potential of HDACIs, with ongoing trials expected.

Conclusions:

  • HDACIs offer a promising therapeutic avenue for breast cancer.
  • Combination therapy involving HDACIs shows enhanced effects.
  • Future research should focus on novel HDACI development and large-scale clinical trials.
Keywords:
Anticancer drugBreast cancerClinical trialsHDAC inhibitorsHDACs

More Related Videos

Utilization of the Soft Agar Colony Formation Assay to Identify Inhibitors of Tumorigenicity in Breast Cancer Cells11:06

Utilization of the Soft Agar Colony Formation Assay to Identify Inhibitors of Tumorigenicity in Breast Cancer Cells

Published on: May 20, 2015

29.7K
Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer07:45

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer

Published on: May 18, 2020

6.9K

Related Concept Videos

Anticholinesterase Agents: Poisoning and Treatment01:26

Anticholinesterase Agents: Poisoning and Treatment

Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.     
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
1.5K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
534
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
577
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
502
Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
10.9K